Daniel Barenboim, Parkinson's disease
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback